Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Pacira Pharmaceuticals buy JPMorgan Chase & Co.

Start price
€28.20
07.03.24 / 50%
Target price
€41.38
07.03.25
Performance (%)
-24.11%
End price
€21.40
08.03.25
Summary
This prediction ended on 08.03.25 with a price of €21.40. The prediction for Pacira Pharmaceuticals disappointed with a performance of -24.11%. JPMorgan_Chase___Co_ has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Pacira Pharmaceuticals 4.902% 4.902% 15.676%
iShares Core DAX® 0.734% 1.458% 17.980%
iShares Nasdaq 100 -2.686% -0.146% 3.810%
iShares Nikkei 225® -2.261% -2.729% 11.679%
iShares S&P 500 -1.346% 0.467% 1.970%

Comments by JPMorgan_Chase___Co_ for this prediction

In the thread Pacira Pharmaceuticals diskutieren
Prediction Buy
Perf. (%) -24.11%
Target price 41.378
Change
Ends at 07.03.25

Pacira BioSciences, Inc. (NASDAQ: PCRX) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $45.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat

In the thread Trading Pacira Pharmaceuticals
Prediction Buy
Perf. (%) -24.11%
Target price 41.378
Change
Ends at 07.03.25

Die von JPMorgan_Chase___Co_ gewählte maximale Laufzeit wurde überschritten

Stopped prediction by JPMorgan_Chase___Co_ for Pacira Pharmaceuticals

Pacira Pharmaceuticals

Start price
Target price
Perf. (%)
€11.10
12.08.24
€9.16
12.08.25
87.39%
13.08.25